The use of autologous chondrocyte implantation for the treatment of cartilage defects in the knee joints
This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta89
Important information about this guidance
Review of Technology Appraisal 16
This guidance replaces 'Autologous cartilage transplantation for full thickness cartilage defects in knee joints' (NICE Technology Appraisal Guidance 16) issued in December 2000.
The Institute reviews each piece of guidance it issues.
The review and re-appraisal of the use of autologous chondrocyte implantation (ACI) for the treatment of cartilage defects in knee joints has resulted in modifications to the guidance. Specifically:
-
the recommendation that ACI should not be used for routine primary treatment has been expanded to include all treatment levels
-
the recommendation on the use of ACI in clinical trials has been revised to recommend that all patients receiving ACI should be enrolled in ongoing or new clinical studies
-
a recommendation has been made that patients should be fully informed of the uncertainties about the long-term effectiveness and the potential adverse effects of this procedure.